$CRIS
CURIS INC

2015 Q1 Form 10-K Financial Statement

#000119312515060006 Filed on February 24, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 2013 Q4
Revenue $1.658M $9.843M $1.524M
YoY Change 29.06% -34.39% -9.62%
Cost Of Revenue $24.43M $340.0K $70.00K
YoY Change 34800.0% 70.0% -99.27%
Gross Profit -$22.77M $9.500M $1.450M
YoY Change -1966.39% -35.81% -118.49%
Gross Profit Margin -1373.34% 96.52% 95.14%
Selling, General & Admin $3.530M $11.04M $2.980M
YoY Change 24.73% -2.21% 3.47%
% of Gross Profit 116.21% 205.52%
Research & Development $4.719M $13.66M $2.960M
YoY Change 50.0% 5.67% -68.84%
% of Gross Profit 143.78% 204.14%
Depreciation & Amortization $40.00K $160.0K $40.00K
YoY Change 0.0% 14.29% 0.0%
% of Gross Profit 1.68% 2.76%
Operating Expenses $4.719M $13.66M $5.940M
YoY Change 50.0% 5.67% -37.47%
Operating Profit -$31.02M -$15.86M -$4.483M
YoY Change 552.64% 68.45% -74.15%
Interest Expense $866.9K $3.749M $290.0K
YoY Change -8.84% -2.41% -72.64%
% of Operating Profit
Other Income/Expense, Net -$826.7K -$2.866M
YoY Change 1.98% -1.35%
Pretax Income -$31.85M -$18.73M -$4.200M
YoY Change 472.84% 52.03% -66.05%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$31.85M -$18.73M -$4.198M
YoY Change 472.4% 52.0% -66.07%
Net Earnings / Revenue -1920.87% -190.28% -275.44%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.475M -$1.090M -$245.2K
COMMON SHARES
Basic Shares Outstanding 103.2M shares 85.80M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2014 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $100.0M $49.80M $58.20M
YoY Change 73.01% -14.43% 4.86%
Cash & Equivalents $23.47M $7.700M $9.591M
Short-Term Investments $76.50M $42.00M $48.60M
Other Short-Term Assets $800.0K $500.0K $500.0K
YoY Change 60.0% 0.0% 25.0%
Inventory
Prepaid Expenses
Receivables $1.769M $2.000M $1.477M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $102.6M $52.20M $60.17M
YoY Change 71.93% -13.29% 5.83%
LONG-TERM ASSETS
Property, Plant & Equipment $364.0K $400.0K $445.7K
YoY Change -10.92% 0.0% 2.65%
Goodwill $8.982M $8.982M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $7.200M $800.0K $10.70M
YoY Change 18.03% -92.52% 234.38%
Other Assets $60.87K $200.0K $104.0K
YoY Change -33.23% -33.33% -34.09%
Total Long-Term Assets $16.76M $10.40M $20.42M
YoY Change 6.62% -49.02% 58.13%
TOTAL ASSETS
Total Short-Term Assets $102.6M $52.20M $60.17M
Total Long-Term Assets $16.76M $10.40M $20.42M
Total Assets $119.3M $62.60M $80.59M
YoY Change 58.31% -22.33% 15.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.782M $2.300M $2.037M
YoY Change 9.33% 15.0% -18.66%
Accrued Expenses $1.365M $2.000M $1.911M
YoY Change 9.5% 5.26% 29.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.584M $5.700M $2.610M
YoY Change 64.61% 119.23%
Total Short-Term Liabilities $9.731M $10.10M $6.559M
YoY Change 24.62% 53.03% 64.84%
LONG-TERM LIABILITIES
Long-Term Debt $21.80M $22.60M $27.95M
YoY Change -18.74% -19.0% -6.35%
Other Long-Term Liabilities $168.3K $200.0K $196.7K
YoY Change -13.56% -77.78% 0.93%
Total Long-Term Liabilities $21.96M $22.80M $28.14M
YoY Change -18.71% -20.83% -6.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.731M $10.10M $6.559M
Total Long-Term Liabilities $21.96M $22.80M $28.14M
Total Liabilities $31.69M $32.80M $35.42M
YoY Change -8.99% -7.34% -0.24%
SHAREHOLDERS EQUITY
Retained Earnings -$811.4M -$760.8M
YoY Change 5.87% 1.65%
Common Stock $900.5M $870.8K
YoY Change 103208.08% 7.42%
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.524M $1.524M
YoY Change 0.0% 70.99%
Treasury Stock Shares 1.223M shares 1.223M shares
Shareholders Equity $87.62M $29.80M $45.17M
YoY Change
Total Liabilities & Shareholders Equity $119.3M $62.60M $80.59M
YoY Change 58.31% -22.33% 15.51%

Cashflow Statement

Concept 2015 Q1 2014 2013 Q4
OPERATING ACTIVITIES
Net Income -$31.85M -$18.73M -$4.198M
YoY Change 472.4% 52.0% -66.07%
Depreciation, Depletion And Amortization $40.00K $160.0K $40.00K
YoY Change 0.0% 14.29% 0.0%
Cash From Operating Activities -$7.760M -$16.81M -$5.510M
YoY Change 46.14% 76.24% -59.81%
INVESTING ACTIVITIES
Capital Expenditures $14.96K $92.00K -$20.00K
YoY Change -39.87% -66.67%
Acquisitions
YoY Change
Other Investing Activities -$40.57M $16.37M -$5.910M
YoY Change -1279.36% -221.62% -49.4%
Cash From Investing Activities -$40.58M $16.27M -$5.930M
YoY Change -1279.65% -219.5% -49.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $64.60M $0.00
YoY Change 35703.16% -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 64.06M -$1.304M 7.250M
YoY Change 35488.89% -106.52% -76.14%
NET CHANGE
Cash From Operating Activities -7.760M -$16.81M -5.510M
Cash From Investing Activities -40.58M $16.27M -5.930M
Cash From Financing Activities 64.06M -$1.304M 7.250M
Net Change In Cash 15.72M -$1.844M -4.190M
YoY Change -1030.18% -41.58% -184.65%
FREE CASH FLOW
Cash From Operating Activities -$7.760M -$16.81M -$5.510M
Capital Expenditures $14.96K $92.00K -$20.00K
Free Cash Flow -$7.775M -$16.91M -$5.490M
YoY Change 46.42% 74.41% -59.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
103178454 shares
CY2002Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
3000000
CY2014Q2 dei Entity Public Float
EntityPublicFloat
120126000
CY2010Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1612322 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6884869 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.44
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1222846 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2010Q1 cris Registered Direct Offering Number Of Warrant Per Unit
RegisteredDirectOfferingNumberOfWarrantPerUnit
1
CY2010Q1 cris Registered Direct Offering Number Of Common Stock Per Unit
RegisteredDirectOfferingNumberOfCommonStockPerUnit
1
CY2010Q1 cris Registered Direct Offering Units
RegisteredDirectOfferingUnits
6449288 shares
CY2010Q1 cris Direct Offering Purchase Price
DirectOfferingPurchasePrice
2.52
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
39875957
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15119730
CY2012Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1488179
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
34267498
CY2012Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
615859
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12747709
CY2012Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
421715
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87081862 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
85859016 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.79
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10077805 shares
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
114904000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1913429
CY2013Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
716786
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6558517
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
298935
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
870819
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6984
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2036864
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-760826561
CY2013Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2610174
CY2013Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
28050291
CY2013Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1267954
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1911479
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
45173585
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
196734
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
178390
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
27945186
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80590808
CY2013Q4 us-gaap Liabilities Fair Value Disclosure Nonrecurring
LiabilitiesFairValueDisclosureNonrecurring
0
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
806660340
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
166200
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2013Q4 us-gaap Liabilities
Liabilities
35417223
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
9046
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9591487
CY2013Q4 us-gaap Goodwill
Goodwill
8982000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
445655
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
47586333
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
114904000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
495260
CY2013Q4 us-gaap Deferred Tax Assets Gross Current
DeferredTaxAssetsGrossCurrent
35000
CY2013Q4 us-gaap Deferred Tax Assets Gross Noncurrent
DeferredTaxAssetsGrossNoncurrent
114869000
CY2013Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
166487
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
15476
CY2013Q4 us-gaap Assets Fair Value Disclosure Nonrecurring
AssetsFairValueDisclosureNonrecurring
0
CY2013Q4 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
120000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11588000
CY2013Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
48588135
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2359084
CY2013Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
1001802
CY2013Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
152496
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
72446000
CY2013Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
23711000
CY2013Q4 us-gaap Long Term Investments
LongTermInvestments
10726685
CY2013Q4 us-gaap Assets
Assets
80590808
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
118000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1477188
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
47592763
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
104034
CY2013Q4 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
13877
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1524029
CY2013Q4 us-gaap Assets Current
AssetsCurrent
60165947
CY2013Q4 us-gaap Restricted Investments
RestrictedInvestments
180364
CY2013Q4 cris Debt Instrument Current Carrying Amount
DebtInstrumentCurrentCarryingAmount
2663677
CY2013Q4 cris Deferred Tax Assets Tax Deferred Interest Expense
DeferredTaxAssetsTaxDeferredInterestExpense
307000
CY2013Q4 cris Deferred Finance Current Costs
DeferredFinanceCurrentCosts
51441
CY2013Q4 cris Deferred Tax Assets Stock Options
DeferredTaxAssetsStockOptions
2723000
CY2013Q4 cris Deferred Finance Non Current Costs
DeferredFinanceNonCurrentCosts
101055
CY2013Q4 cris Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
716786
CY2013Q4 cris Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
3891000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87253657 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86030811 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.66
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
121919000
CY2014Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
24529 sqft
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7534372 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.45
CY2014Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1222846 shares
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.55
CY2014Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1373517 shares
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1373517 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11319619 shares
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1929564
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10066867
CY2014Q4 us-gaap Interest Payable Current
InterestPayableCurrent
286075
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
872537
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10997
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2349183
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-779555295
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
59000
CY2014Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
5709985
CY2014Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
22664787
CY2014Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1386226
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2007699
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
29783626
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
174018
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
212548
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2086000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
700000
CY2014Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
22589058
CY2014Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62613569
CY2014Q4 us-gaap Liabilities Fair Value Disclosure Nonrecurring
LiabilitiesFairValueDisclosureNonrecurring
0
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
810001410
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
122850
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
676000
CY2014Q4 us-gaap Liabilities
Liabilities
32829943
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4883
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
651000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7747411
CY2014Q4 us-gaap Goodwill
Goodwill
8982000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
407738
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
659000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
42791550
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
121919000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
489844
CY2014Q4 us-gaap Deferred Tax Assets Gross Current
DeferredTaxAssetsGrossCurrent
39000
CY2014Q4 us-gaap Deferred Tax Assets Gross Noncurrent
DeferredTaxAssetsGrossNoncurrent
121880000
CY2014Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
152610
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
15880
CY2014Q4 us-gaap Assets Fair Value Disclosure Nonrecurring
AssetsFairValueDisclosureNonrecurring
0
CY2014Q4 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
120000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
12212000
CY2014Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
42002782
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2337302
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
659000
CY2014Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
108180
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
78289000
CY2014Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
24059000
CY2014Q4 us-gaap Long Term Investments
LongTermInvestments
788768
CY2014Q4 us-gaap Assets
Assets
62613569
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
114000
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4720000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1960995
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
42802547
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
67544
CY2014Q4 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
13877
CY2014Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1524029
CY2014Q4 us-gaap Assets Current
AssetsCurrent
52214909
CY2014Q4 us-gaap Restricted Investments
RestrictedInvestments
166487
CY2014Q4 cris Debt Instrument Current Carrying Amount
DebtInstrumentCurrentCarryingAmount
5748059
CY2014Q4 cris Operating Lease Cash Obligation
OperatingLeaseCashObligation
4401000
CY2014Q4 cris Stock Issued During Period Due To Exercise Of Warrants
StockIssuedDuringPeriodDueToExerciseOfWarrants
238805 shares
CY2014Q4 cris Deferred Finance Current Costs
DeferredFinanceCurrentCosts
43616
CY2014Q4 cris Deferred Tax Assets Stock Options
DeferredTaxAssetsStockOptions
3534000
CY2014Q4 cris Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber
10980633 shares
CY2014Q4 cris Deferred Finance Non Current Costs
DeferredFinanceNonCurrentCosts
64564
CY2014Q4 cris Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
2.66
CY2014Q4 cris Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
3591000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
640000 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.20
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.34
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.019 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.70 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
400000 shares
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.021 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.65 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
640000 shares
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.09
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
400000 shares
CY2014Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.75
CY2002 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
1047707 shares
CY2002 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
891274
CY2010 cris Proceeds From Registered Direct Offering Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts
14942317
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2651152 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.27
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9539577
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.052 pure
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
82339493 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.430 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.001 pure
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.085 pure
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11451322 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.008 pure
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2716000
CY2013 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-13918
CY2013 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
351089
CY2013 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-95197
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-22143
CY2013 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2013 us-gaap Licenses Revenue
LicensesRevenue
10000000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
116639
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-9416409
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12344155
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2905603
CY2013 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
20880756
CY2013 us-gaap Royalty Revenue
RoyaltyRevenue
3942136
CY2013 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
261475
CY2013 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-771393
CY2013 us-gaap Revenues
Revenues
15002032
CY2013 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
65827658
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
153009
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-12322012
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
164650
CY2013 us-gaap Interest Paid
InterestPaid
2913999
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
569124
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2651152
CY2013 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-22143
CY2013 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2013 us-gaap Interest Expense
InterestExpense
3841646
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12926834
CY2013 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
104842
CY2013 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2013 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
632755
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3156222
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-771393
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
141522
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
20000892
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4016383
CY2013 us-gaap Royalty Expense
RoyaltyExpense
197796
CY2013 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2013 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-13617537
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
24418441
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
614000
CY2013 us-gaap Paid In Kind Interest
PaidInKindInterest
713968
CY2013 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
52349212
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11293811
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
181821
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
3002241
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2091000
CY2013 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
2782435
CY2013 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
145000
CY2013 cris Effective Income Tax Rate Reconciliation Fair Value Of Warrants
EffectiveIncomeTaxRateReconciliationFairValueOfWarrants
0.021 pure
CY2013 cris Written Off Plant And Equipment Net Of Accumulated Depreciation
WrittenOffPlantAndEquipmentNetOfAccumulatedDepreciation
329000
CY2013 cris Research And Development Revenue
ResearchAndDevelopmentRevenue
1059896
CY2013 cris Effective Income Tax Reconciliation Net Operating Loss Expirations
EffectiveIncomeTaxReconciliationNetOperatingLossExpirations
-0.052 pure
CY2013 cris Effective Income Tax Rate Reconciliation Interest Expense
EffectiveIncomeTaxRateReconciliationInterestExpense
-0.025 pure
CY2013 cris Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees
351089
CY2013 cris Available For Sale Securities Weighted Average Maturity
AvailableForSaleSecuritiesWeightedAverageMaturity
P4M21D
CY2013 cris Percentage Research And Development Expenses
PercentageResearchAndDevelopmentExpenses
0.05 pure
CY2013 cris Adjustments To Additional Paid In Capital Stock Issued Under Atm Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedUnderAtmIssuanceCosts
641052
CY2013 cris Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
16245984
CY2013 cris Treasury Stock Non Cash
TreasuryStockNonCash
632755
CY2014 us-gaap Revenue Recognition Milestone Method Milestone
RevenueRecognitionMilestoneMethodMilestone
The Company has agreed to make each of the following one-time payments to Debiopharm (i) $3,000,000 within 30 days after the first dosing of the first patient in the first Phase 3 clinical trial of Debio 0932; and (ii) $10,000,000 within 30 days after receipt of the first marketing approval for Debio 0932 in the United States of America or any specified major European market (whichever occurs first);
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.049 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3140855 shares
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.86
CY2014 dei Document Type
DocumentType
10-K
CY2014 dei Entity Registrant Name
EntityRegistrantName
CURIS INC
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014 dei Trading Symbol
TradingSymbol
CRIS
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
918874 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.79
CY2014 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2014 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(1)</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>OPERATIONS</b></font></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 8%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2">Curis, Inc. is a biotechnology company seeking to develop and commercialize innovative drug candidates for the treatment of human cancers. As used throughout these consolidated financial statements, the term &#x201C;the Company&#x201D; refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term &#x201C;Curis&#x201D; refers to Curis, Inc.</font></p> <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-LEFT: 8%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company conducts its research and development programs both internally and through strategic collaborations. The Company is leveraging its experience in targeting signaling pathways to develop drug candidates including CUDC-907, a dual histone deacetylase, or HDAC and phosphoinositide-3 kinase, or PI3K, inhibitor, CUDC-427, a small molecule antagonist of the inhibitor of apoptosis, or IAP, proteins, and CUDC-305, a Heat Shock Protein 90, or HSP90, inhibitor. Erivedge<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>, the first and only approved medicine for the treatment of advanced basal cell carcinoma, or BCC, is being commercialized by F. Hoffmann-La Roche Ltd., or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 8%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2">In January 2015, the Company entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited, or Aurigene, a specialized, discovery stage biotechnology company developing novel therapies to treat cancer and inflammatory diseases. The collaboration provides for inclusion of multiple programs, with Curis having the option to exclusively license compounds once a development candidate is nominated within each respective program. The first two programs under the collaboration are orally-available small molecule antagonists of programmed death ligand-1 (PD-L1) in the immuno-oncology field and orally-available small molecule inhibitors of Interleukin-1 receptor-associated kinase 4 (IRAK4) in the precision oncology field.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 8%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the health care industry and would be regulated in the United&#xA0;States by the Food and Drug Administration, or FDA, and in overseas markets by similar regulatory authorities.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 8%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company is subject to risks common to companies in the biotechnology industry as well as risk factors that are specific to the Company&#x2019;s business, including, but not limited to: the Company&#x2019;s reliance on Genentech and Roche to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress it&#x2019;s clinical development in indications other than BCC; the Company&#x2019;s reliance on Aurigene to successfully discover and preclinically develop drug candidates under the parties&#x2019; collaboration agreement, the Company&#x2019;s ability to advance and expand its research and development programs; the Company&#x2019;s ability to obtain adequate financing to fund its operations; the ability of the Company&#x2019;s wholly owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its loan agreement with BioPharma Secured Debt Fund II Sub, S.&#xE0; r.l., a Luxembourg limited liability company managed by Pharmakon Advisors, or BioPharma-II; the Company&#x2019;s ability to obtain and maintain necessary intellectual property protection; development by the Company&#x2019;s competitors of new or better technological innovations; dependence on key personnel; the Company&#x2019;s ability to comply with regulatory requirements; and the Company&#x2019;s ability to execute on its overall business strategies.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 8%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s future operating results will largely depend on the magnitude of payments that it receives and makes under its current and potential future corporate collaborators and the progress of drug candidates currently in its development pipeline. The results of the Company&#x2019;s operations will vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: Roche and Genentech&#x2019;s ability to successfully commercialize Erivedge; positive results in Genentech&#x2019;s ongoing clinical trials; Aurigene&#x2019;s ability to successfully discover and develop preclinically programs under the Company&#x2019;s collaboration with Aurigene, as well as the Company&#x2019;s decision to exclusively license and further develop programs under this collaboration; the timing, outcome and cost of the Company&#x2019;s preclinical studies and clinical trials for its drug candidates; and the Company&#x2019;s ability to successfully enter into one or more material outlicensing or collaboration agreements for its proprietary drug candidates.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 8%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company anticipates that existing cash, cash equivalents and investments at December&#xA0;31, 2014 should enable it to maintain current and planned operations into 2016. The Company&#x2019;s ability to continue funding its planned operations beyond this period is dependent upon, among other things, the success of its collaborations with Genentech and the Leukemia&#xA0;&amp; Lymphoma Society, or LLS, including its receipt of additional contingent cash payments under these collaborations; its ability to control expenses and its ability to raise additional funds through equity or debt financings, new collaborations or other sources of financing. The Company may not be able to successfully raise additional funds or enter into or continue any corporate collaborations and the timing, amount and likelihood of the Company receiving payments under such collaborations is highly uncertain. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay spending on its research and/or development programs.</font></p> </div>
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16812744
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2275500 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
1040000 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.019 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
0 shares
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(a)</td> <td valign="top" align="left">USE OF ESTIMATES</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The preparation of the Company&#x2019;s consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts and disclosure of revenue, expenses and certain assets and liabilities at the balance sheet date. Such estimates include revenue recognition, including estimates of the performance obligations under the Company&#x2019;s collaboration agreements; the estimated repayment term of the Company&#x2019;s debt and related short- and long-term classification; the collectibility of receivables; the carrying value of property and equipment and intangible assets; the assumptions used in the Company&#x2019;s valuation of stock-based compensation and the value of certain investments and liabilities, including our warrant liability. Actual results may differ from such estimates.</p> </div>
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
85974535 shares
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-12-31
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.375 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.001 pure
CY2014 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
4.11
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.65
CY2014 dei Entity Central Index Key
EntityCentralIndexKey
0001108205
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.032 pure
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12693136 shares
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(m)</td> <td valign="top" align="left">CONCENTRATION OF RISK</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, short- and long-term investments. The Company invests directly in commercial paper of financial institutions and corporations with A-/Aa3 or better long-term ratings and A-1/P-1 short term debt ratings and U.S. Treasury securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company&#x2019;s credit risk related to investments is reduced as a result of the Company&#x2019;s policy to limit the amount invested in any one issue.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company&#x2019;s accounts receivable at December&#xA0;31, 2014, represents amounts due from collaborators, primarily for royalties earned on sales of Erivedge by Genentech and Roche.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company relies on third parties to supply certain raw materials necessary to produce its drug candidates, including CUDC-907 and CUDC-427, for preclinical studies and clinical trials. There are a small number of suppliers for certain raw materials that the Company uses to manufacture its drug candidates.</p> </div>
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.016 pure
CY2014 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2018-02-28
CY2014 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
114812 shares
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2907000
CY2014 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-13877
CY2014 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-169652
CY2014 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4013
CY2014 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2014 us-gaap Repayments Of Debt
RepaymentsOfDebt
8901330
CY2014 us-gaap Licenses Revenue
LicensesRevenue
3000000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2409
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-15862249
CY2014 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
1750
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18732747
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2866485
CY2014 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
282799
CY2014 us-gaap Royalty Revenue
RoyaltyRevenue
6757023
CY2014 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-716786
CY2014 us-gaap Revenues
Revenues
9843481
CY2014 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
41399246
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
92209
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-18728734
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
165103
CY2014 us-gaap Interest Paid
InterestPaid
4386109
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
483807
CY2014 us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
1587154
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3140855
CY2014 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4013
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
392945
CY2014 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2014 us-gaap Interest Expense
InterestExpense
3748374
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13659398
CY2014 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
89120
CY2014 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1844076
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-716786
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
155083
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-1304355
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
282799
CY2014 us-gaap Royalty Expense
RoyaltyExpense
339578
CY2014 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2014 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
16273023
CY2014 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
1750
CY2014 us-gaap Costs And Expenses
CostsAndExpenses
25705730
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
614000
CY2014 us-gaap Paid In Kind Interest
PaidInKindInterest
-713968
CY2014 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
57748851
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11706754
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
360866
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
3059989
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
105000
CY2014 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
1915990
CY2014 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
172000
CY2014 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
-1587154
CY2014 cris Obligation Limit
ObligationLimit
2.50 pure
CY2014 cris Tax Credit Carryforward Ending Expiration Year
TaxCreditCarryforwardEndingExpirationYear
2034
CY2014 cris Effective Income Tax Rate Reconciliation Fair Value Of Warrants
EffectiveIncomeTaxRateReconciliationFairValueOfWarrants
0.013 pure
CY2014 cris Written Off Plant And Equipment Net Of Accumulated Depreciation
WrittenOffPlantAndEquipmentNetOfAccumulatedDepreciation
139000
CY2014 cris Term Of Warrants Period
TermOfWarrantsPeriod
P5Y
CY2014 cris Additional Period For Lease
AdditionalPeriodForLease
P5Y
CY2014 cris Research And Development Revenue
ResearchAndDevelopmentRevenue
86458
CY2014 cris Diligence Period
DiligencePeriod
P5Y
CY2014 cris Effective Income Tax Reconciliation Net Operating Loss Expirations
EffectiveIncomeTaxReconciliationNetOperatingLossExpirations
-0.028 pure
CY2014 cris Class Of Warrant Or Right Expiration Date
ClassOfWarrantOrRightExpirationDate
2015-01-27
CY2014 cris Net Operating Losses Expiration Year
NetOperatingLossesExpirationYear
2014
CY2014 cris Tax Credit Carryforward Beginning Expiration Year
TaxCreditCarryforwardBeginningExpirationYear
2019
CY2014 cris Tax Credit Carryforward Expiration
TaxCreditCarryforwardExpiration
Starting in 2019 through 2034
CY2014 cris Effective Income Tax Rate Reconciliation Interest Expense
EffectiveIncomeTaxRateReconciliationInterestExpense
-0.016 pure
CY2014 cris Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees
-80866
CY2014 cris Contingent Obligations
ContingentObligations
4125000
CY2014 cris Number Of Operating Leases
NumberOfOperatingLeases
1 CreditFacility
CY2014 cris Percentage Research And Development Expenses
PercentageResearchAndDevelopmentExpenses
0.05 pure
CY2014 cris Share Based Compensation Plans
ShareBasedCompensationPlans
2 Plans
CY2014 cris Class Of Warrant Unexercised Month And Year
ClassOfWarrantUnexercisedMonthAndYear
2015-01
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3268689 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.99
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-15193305
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.058 pure
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
79059153 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.050 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.017 pure
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.008 pure
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11811278 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.021 pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2525000
CY2012 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-41632
CY2012 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
355222
CY2012 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
434763
CY2012 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-18806
CY2012 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2012 us-gaap Licenses Revenue
LicensesRevenue
14000000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-40959
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-18619807
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16435713
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2202900
CY2012 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
6239343
CY2012 us-gaap Royalty Revenue
RoyaltyRevenue
1529644
CY2012 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
160240
CY2012 us-gaap Revenues
Revenues
16971991
CY2012 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
69153956
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
104975
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-16416907
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
149937
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
865997
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3268689
CY2012 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
964000
CY2012 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-18806
CY2012 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2012 us-gaap Interest Expense
InterestExpense
204167
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15492302
CY2012 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
5769
CY2012 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2372021
CY2012 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2257130
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
126537
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
35824539
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5105699
CY2012 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
9500000
CY2012 us-gaap Royalty Expense
RoyaltyExpense
176482
CY2012 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2012 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-23003255
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
35591798
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
614000
CY2012 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
46214044
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10423014
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
20316
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
3623911
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6145000
CY2012 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
1223602
CY2012 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
153000
CY2012 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
30000000
CY2012 cris Written Off Plant And Equipment Net Of Accumulated Depreciation
WrittenOffPlantAndEquipmentNetOfAccumulatedDepreciation
418000
CY2012 cris Research And Development Revenue
ResearchAndDevelopmentRevenue
1442347
CY2012 cris Issuance Of Common Stock To Licensees
IssuanceOfCommonStockToLicensees
964000
CY2012 cris Effective Income Tax Reconciliation Net Operating Loss Expirations
EffectiveIncomeTaxReconciliationNetOperatingLossExpirations
-0.360 pure
CY2012 cris Receivable For Issuances Of Common Stock
ReceivableForIssuancesOfCommonStock
14366
CY2012 cris Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees
355222
CY2012 cris Number Of University Licensors
NumberOfUniversityLicensors
2 Licensors
CY2012 cris Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
879080
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-4962294
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
85917592 shares
CY2012 cris Adjustments To Additional Paid In Capital Stock Issued Under Atm Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedUnderAtmIssuanceCosts
27356
CY2012 cris Debt Issuance Costs Unpaid And Accrued
DebtIssuanceCostsUnpaidAndAccrued
261475
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
80096650 shares
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4357364
CY2013Q1 us-gaap Revenues
Revenues
871435
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4753343
CY2014Q1 us-gaap Revenues
Revenues
1284633
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-5563936
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
81128475 shares
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-706196
CY2013Q2 us-gaap Revenues
Revenues
5404377
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-1293848
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
85963836 shares
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1544787
CY2014Q2 us-gaap Revenues
Revenues
4801285
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-1895785
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
82456708 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
130368
CY2013Q3 us-gaap Revenues
Revenues
7202083
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-1867838
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86004857 shares
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4753031
CY2014Q3 us-gaap Revenues
Revenues
1764864
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-5580143
CY2013Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
85741278 shares
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2013Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4483217
CY2013Q4 us-gaap Revenues
Revenues
1524137
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-4198032
CY2014Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86010499 shares
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4811088
CY2014Q4 us-gaap Revenues
Revenues
1992699
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-5688870

Files In Submission

Name View Source Status
0001193125-15-060006-index-headers.html Edgar Link pending
0001193125-15-060006-index.html Edgar Link pending
0001193125-15-060006.txt Edgar Link pending
0001193125-15-060006-xbrl.zip Edgar Link pending
cris-20141231.xml Edgar Link completed
cris-20141231.xsd Edgar Link pending
cris-20141231_cal.xml Edgar Link unprocessable
cris-20141231_def.xml Edgar Link unprocessable
cris-20141231_lab.xml Edgar Link unprocessable
cris-20141231_pre.xml Edgar Link unprocessable
d846591d10k.htm Edgar Link pending
d846591dex1029.htm Edgar Link pending
d846591dex1032.htm Edgar Link pending
d846591dex1034.htm Edgar Link pending
d846591dex1035.htm Edgar Link pending
d846591dex21.htm Edgar Link pending
d846591dex231.htm Edgar Link pending
d846591dex311.htm Edgar Link pending
d846591dex312.htm Edgar Link pending
d846591dex321.htm Edgar Link pending
d846591dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g846591g20f06.jpg Edgar Link pending
g846591g63e57.jpg Edgar Link pending
g846591g77z34.jpg Edgar Link pending
g846591g78z09.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending